Vaccine to Protect Against Infections by Salmonella

Track Code:

15KU036L

Summary:

The invention relates to protecting against Salmonella-type pathogens and more particularly, compositions and methods for immunizing against infection by typhoidal and non-typhoidal Salmonella serovars.

Overview:

People and animals get sick and may die after being infected with the gastrointestinal pathogen Salmonella.  Salmonella causes a wide range of human and animal diseases from typhoid to diarrhea.  Currently there are no vaccines for Salmonella typhimurium and such serovars.  S. enterica serotype Typhimurium and numerous other serotypes are known as the non-typhoidal Salmonella (NTS) causing salmonellosis, a severe gastroenteritis in healthy individuals, and scours in young livestock and a carrier state in older animals and poultry.  Better than treatment, is prevention, and the best prevention against infectious diseases remains vaccination conferring protection and eliminating the need for antibiotics to treat these infections.  The vaccine in this invention is vastly different from what is available on the market today.  Proof-of-concept in mice has been completed demonstrating that the vaccine elicited an immune response that provided significant protection to the mice against a Salmonella challenge by two unique serotypes.

Applications:

Prevention of Salmonella diseases

How it works:

The invention is the creation of a fusion protein that is broadly protective across all Salmonella and is required for infection by Salmonella.  Methods of immunization comprise the use of the antigenic molecules.  The vaccine comprises a therapeutically effective amount of the fusion protein, comprising at least one fusion protein from Salmonella pathogenicity island 1 (SPI-1) and/or Salmonella pathogenicity island 2 (SPI-2) or variants thereof.

Benefits:

Broadly protective against all species for Salmonella.

Why it is better:

The vaccine product when commercialized, will offer protection against all 2500 serovars.  This vaccine is not based on Lipopolysaccharide (LPS) protection but are broadly protective based on the requirements of proteins for infection.

Other Applications:

Vaccines against many Gram negative bacterial pathogens.

Licensing Associate:

Aswini Betha, PhD · abetha@ku.edu · 913-588-5713

Category(s):

Subcategory(s):


Additional Information

Inventor(s):

  • Wendy Picking, PhD
  • William Picking, PhD

Patent(s):

  • US20160220655A1

Status:

  • Patented
Events
KU Today